'Functional cure' of HIV infection: The role of immunotherapy

Immunotherapy

Volumn 4, Issue 3, 2012, Pages 245-248

  García, Felipe ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

dendritic cell; functional cure; HIV; immunotherapy; therapeutic vaccine

Indexed keywords

DNA; VIRUS ANTIGEN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HERPES VIRUS INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; VIRUS RECOMBINANT;

ANIMALS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; VIRUS REPLICATION;

EID: 84858325821     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.2     Document Type: Review

References (28)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13), 853-860 (1998). (Pubitemid 28135961)
2. Plana M, García F, Gallart MT, et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 14, 1921-1933 (2000).
3. 4+ T cells. Nat. Med. 9(6), 727-728 (2003). (Pubitemid 36749221)
4. Buzón MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16(4), 460-465 (2010).
5. Plana M, García F, Gallart MT, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease. Lancet 352, 1194-1195 (1998). (Pubitemid 28458540)
6. Gamberg J, Barret L, Bowmer M, Howley C, Grant M. Factors related to loss of HIV-specific cytotoxic T lymphocyte activity. AIDS 18, 597-604 (2004). (Pubitemid 38393458)
7. García F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13, F79-F86 (1999). (Pubitemid 29408440)
8. Cohen J. New HIV infections drop, but treatment demands rise. Science 330, 1301 (2010).
9. Cohen J. The emerging race to cure HIV infections. Science 332(6031), 784-789 (2011).
10. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 360(7), 692-698 (2009).
11. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5D32/D32 stem cell transplantation. Blood 117(10), 2791-2799 (2011).
12. Karpas A, Hewlett IK, Hill F, et al. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc. Natl Acad. Sci. USA 87(19), 7613-7617 (1990). (Pubitemid 20341767)
13. Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 361(16), 1548-1559 (2009).
14. García F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 15, F29-F40 (2001). (Pubitemid 32549858)
15. García F, Plana M, Arnedo M, et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions. A randomized study. AIDS 17, 43-51 (2003). (Pubitemid 36106297)
16. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 305(5681), 205-208 (2004). (Pubitemid 38886726)
17. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J. Acquir. Immune Defic. Syndr. 55(2), 262-270 (2010).
18. 4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296 (2006).
19. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 10(6)/L CD4 cell counts: a randomized controlled trial. JAMA 284(17), 2193-2202 (2000).
20. Gorse GJ, Simionescu RE, Patel GB. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1. Clin. Vaccine Immunol. 13(1), 26-32 (2006).
21. Dorrell L, Yang H, Iversen AK, et al. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 19(12), 1321-1323 (2005). (Pubitemid 41224902)
22. Papagno L, Alter G, Assoumou L, et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 25(1), 27-36 (2011).
23. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998). (Pubitemid 28155090)
24. García F, Routy JP. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 29(38), 6454-6463 (2011).
25. Lu W, Arraes L, Ferreira W, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10, 1359-1365 (2004). (Pubitemid 40022718)
26. García F, Climent N, Assoumou L, et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis. 203(4), 473-478 (2011).
27. García F, Lejeune M, Climent N, et al. Therapeutic immunization with dendritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients. J. Infect. Dis. 195, 1680-1685 (2005). (Pubitemid 40656756)
28. Routy JP, Angel J, Vezina S, et al. Final analysis of a Phase 2 study of an autologous DC immunotherapy (AGS-004) showed positive outcomes in primary endpoint of viral load control, and favorable safety and immunogenicity profile, in subjects undergoing structured treatment interruption of ART. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 385).